GlassScriptPhysician profile
Vanessa Sandifer
NPI 1104002898
$14,355.25
in general payments reported to CMS, 2019-2025
61 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $1,589 · 2021: $2,063 · 2022: $2,243 · 2023: $2,242 · 2024: $2,320 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,478.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,877.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,635.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,137.30 | 2019-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Dexcom, INC. | $972.23 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $694.00 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novartis Pharmaceuticals Corporation | $686.62 | 2022-2025 | |
| Insulet Corporation | $619.64 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $611.78 | 2019-2022 | |
| Corcept Therapeutics | $551.95 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $503.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.26 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $400.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $394.24 | 2019-2023 | Steglatro, Steglujan, Segluromet |
| Recordati_rare_diseases_inc. | $343.14 | 2020-2025 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $314.95 | 2020-2025 | Nexletol |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.76 | 2019-2023 | Cycloset |
| Amneal Pharmaceuticals LLC | $174.43 | 2020-2024 | Unithroid |
| Medtronic, INC. | $171.32 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $158.87 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $158.69 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $156.50 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $150.09 | 2019-2024 | |
| Abbvie INC. | $148.82 | 2019-2025 | Ubrelvy |
| Grt US Holding, INC. | $120.99 | 2021-2022 | |
| Becton, Dickinson and Company | $109.56 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $105.89 | 2022-2025 | Yorvipath |
| Beta Bionics, INC. | $105.12 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Valeritas, INC. | $102.92 | 2019 | |
| Horizon Therapeutics Plc | $101.13 | 2022-2023 | Tepezza |
| Ibsa Pharma INC. | $93.21 | 2020-2023 | Tirosint, Licart |
| Kyowa Kirin, INC. | $85.92 | 2023-2025 | Crysvita |
| Sequel Med Tech, LLC | $77.52 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $76.50 | 2024-2025 | |
| Antares Pharma, INC. | $75.65 | 2024-2025 | Xyosted |
| Amryt Pharma Holdings LTD | $75.62 | 2023 | Mycapssa |
| Cequr Corporation | $74.23 | 2024-2025 | Cequr Simplicity |
| Astellas Pharma US INC | $53.47 | 2023-2025 | Veozah |
| Zealand Pharma US, INC. | $40.42 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.91 | 2019-2020 | |
| Embecta Corp. | $36.24 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Acella Pharmaceuticals, LLC | $31.05 | 2024-2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $28.81 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $28.24 | 2024 | Strensiq |
| Shire North American Group INC | $27.91 | 2019 | |
| Ascensia Diabetes Care US INC. | $27.50 | 2021-2025 | |
| Nalpropion Pharmaceuticals LLC | $22.68 | 2019 | |
| Eisai INC. | $22.28 | 2019 | |
| Radius Health, INC. | $20.58 | 2023 | Tymlos |
| Alfasigma USA, INC. | $19.62 | 2020 | |
| Halozyme INC | $18.96 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $18.78 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $17.81 | 2025 | Baqsimi |
| Vifor Pharma, INC. | $17.39 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $17.05 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.06 | 2019 | |
| Amarin Pharma, INC. | $14.03 | 2019 | |
| Tolmar, INC. | $13.26 | 2024 | |
| Medtronic Minimed, INC. | $12.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.27 | 2020 | |
| Senseonics, Incorporated | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Sandifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.